
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The directors take responsibility for this announcement.
Subscription for New Ordinary Shares
(
The board of the directors of the Company (the "Board") is pleased to confirm that several shareholders have entered into agreements to subscribe a total of
Both the proceeds of the Subscription were received, and the Subscription Shares allotted on
As outlined in the Company's half yearly financial report announced on
Total Voting Rights & Significant Shareholder Disclosures
Following Admission, the issued share capital of the Company will comprise 85,502,843 Ordinary Shares, with one voting right per Ordinary Share. The Company does not hold any shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 85,502,843.
Following Admission, the Significant Shareholders of the Company will be as set out below. The Option Agreements have disclosable holdings under the Disclosure Guidance & Transparency Rules and are Significant Shareholders under the AQSE rules. An updated list of Significant Shareholders (with Option defined as per the announcement of
Significant Shareholder |
Subscription Shares Held |
Total Ordinary Shares Held |
% of Ordinary Shares Held |
Shares Under Option |
% of Shares Under Option |
|
|
|
|
|
|
Nistad Group AS |
0 |
12,500,000 |
14.62% |
0 |
0.00% |
|
20,000 |
9,145,000 |
10.70% |
3,333,334 |
3.90% |
|
20,000 |
7,500,000 |
8.77% |
3,333,334 |
3.90% |
|
20,000 |
7,190,000 |
8.41% |
3,333,334 |
3.90% |
|
20,000 |
6,617,661 |
7.74% |
2,000,000 |
2.34% |
|
20,000 |
6,038,735 |
7.06% |
3,333,334 |
3.90% |
|
20,000 |
5,074,058 |
5.93% |
3,333,334 |
3.90% |
|
0 |
2,875,001 |
3.36% |
0 |
0.00% |
*
Enquiries:
|
|
AQSE Corporate Adviser: |
020 3328 5656 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the